UK’s NICE recommends Iluvien for DME

2 October 2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending Iluvien (fluocinolone acetonide intravitreal implant) as an option for the treatment of chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.

Iluvien is licensed to US drugmaker Alimera Sciences' (Nasdaq: ALIM) from Australia’s pSivida (Nasdaq: PSDV), a specialty pharmaceutical company developing sustained release drugs for treatment of back-of-the-eye diseases.

Chronic diabetic macular edema causes blurred or double vision. Iluvien is recommended as an option for treating chronic diabetic macular edema that is insufficiently responsive to available therapies only if: the implant is to be used in an eye with an intraocular (pseudophakic) lens; and the manufacturer makes it available to the National Health Service (NHS) under the terms agreed with the UK Department of Health as part of a patient access scheme.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK